论文部分内容阅读
文献报告,血清NSE值在小细胞肺癌患者明显上升,而非小细胞肺癌及其它恶性肿瘤亦有上升,故此作为新的肿瘤标志受到注目。作者使用荣研提供的NSE(γ-烯醇化酶)药盒,对包括良、恶性在内的各种疾患118例及7例正常人的血清NSE值作了测定,并就其临床价值加以探讨。病例及测定方法:21～83岁的男女患者125例,其中恶性肿瘤105例(肺癌为38例),良性疾患13例,7例正常人为对照组。测定方法系采用RIA(双
According to reports in the literature, serum NSE values have risen significantly in patients with small cell lung cancer, and non-small cell lung cancers and other malignancies have also risen. As a result, they have attracted attention as new tumor markers. The authors used the NSE (Y-enolase) kit provided by Rongyan to measure the serum NSE values of 118 patients with various diseases including benign and malignant diseases and 7 normal persons, and discussed their clinical value. . Cases and methods: There were 125 male and female patients aged 21 to 83 years old, including 105 malignant tumors (38 lung cancers), 13 benign diseases, and 7 normal controls. Measurement method using RIA (double